Tashiro C, Setoguchi S, Fukuda T, Marubayashi N
Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., Fukuoka, Japan.
Chem Pharm Bull (Tokyo). 1993 Jun;41(6):1074-8. doi: 10.1248/cpb.41.1074.
Mosapramine (1) is a new neuroleptic drug with an asymmetric carbon atom (8a) in its imidazopyridine ring. The enantiomers of this agent were synthesized to compare their biological activities, such as antiapomorphine activity, affinity for dopamine D2 receptor and acute toxicity. The key intermediates, (R)-(-)- and (S)-(+)-2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo[1,2-a]pyridine- 3-spiro-4'-piperidines, were prepared by optical resolution of the corresponding (+/-)-compound and were treated with 3-chloro-5-(3-methanesulfonyloxypropyl)-10,11-dihydro-5H-dibenz[b, f]azepine to afford (R)-(-)-1 and (S)-(+)-1, respectively. There were few differences in the examined biological activities of the two enantiomers as their dihydrochlorides.
莫沙必利(1)是一种新型抗精神病药物,其咪唑并吡啶环中含有一个不对称碳原子(8a)。合成了该药物的对映体以比较它们的生物活性,如抗阿扑吗啡活性、对多巴胺D2受体的亲和力和急性毒性。关键中间体,(R)-(-)-和(S)-(+)-2-氧代-1,2,3,5,6,7,8,8a-八氢咪唑并[1,2-a]吡啶-3-螺-4'-哌啶,通过相应的(±)-化合物的拆分制备,并分别用3-氯-5-(3-甲磺酰氧基丙基)-10,11-二氢-5H-二苯并[b,f]氮杂䓬处理,得到(R)-(-)-1和(S)-(+)-1。两种对映体的盐酸盐在检测的生物活性方面几乎没有差异。